Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 704

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 6
Chunk 704
---
 Financial Statements

ENDRA Life Sciences Inc.

December 31, 2024

  Page     Report of Independent Registered Public Accounting Firm - (Firm ID 587) F-1     Consolidated Balance Sheets as of December 31, 2024 and 2023 F-2     Consolidated Statements of Operations for the years ended December 31, 2024 and 2023 F-3     Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2024 and 2023 F-4     Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023 F-5     Notes to Consolidated Financial Statements for the years ended December 31, 2024 and 2023 F-6 

 52Table of Contents

 RBSM LLP  Houston Office: 7915 FM 1960 West, Ste. 220Houston, Texas 77070 www.rbsmllp.com 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of

ENDRA Life Sciences Inc. and Subsidiaries

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of ENDRA Life Sciences Inc. and Subsidiaries (collectively, the “Company”) as of December 31, 2024 and 2023, the related consolidated statements of operations, shareholders’ equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes and schedules (collectively referred to as the “financial statements”).  In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024 and 2023 in conformity with accounting principles generally accepted in the United States of America.

The Company’s Ability to Continue as a Going Concern

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 2 to the accompanying consolidated financial statements, the Company has suffered recurring losses from operations, generated negative cash flows from operating activities, has an accumulated deficit and has stated that substantial doubt exists about Company’s